NASDAQ:STAA

STAAR Surgical - STAA Stock Forecast, Price & News

$63.51

-0.11 (-0.17%)

(As of 03/27/2023 05:16 PM ET)

Add

Compare

Today's Range: $62.44
▼
$64.70
50-Day Range: $55.39
▼
$79.34
52-Week Range: $46.35
▼
$112.27

Volume: 368,765 shs
Average Volume: 789,924 shs
Market Capitalization: $3.06 billion

P/E Ratio: 81.42
Dividend Yield: N/A
Price Target: $82.20

Institutional Ownership

STAAR Surgical MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 29.4% Upside
$82.20 Price Target
Short Interest: Bearish
10.55% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.56
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$4.36 M Bought Last Quarter
Proj. Earnings Growth: 104.48%
From $0.67 to $1.37 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.04 out of 5 stars

Medical Sector

26th out of 995 stocks

Ophthalmic Goods Industry

1st out of 7 stocks

4.4

Analyst's Opinion

Consensus Rating
STAAR Surgical has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $82.20, STAAR Surgical has a forecasted upside of 29.4% from its current price of $63.51.
Amount of Analyst Coverage
STAAR Surgical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
10.55% of the outstanding shares of STAAR Surgical have been sold short.
Short Interest Ratio / Days to Cover
STAAR Surgical has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in STAAR Surgical has recently increased by 6.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
STAAR Surgical does not currently pay a dividend.
Dividend Growth
STAAR Surgical does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
STAAR Surgical has received a 58.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Intraocular lenses" product. See details.
Environmental Sustainability
The Environmental Impact score for STAAR Surgical is -0.73.

2.5

News and Social Media Coverage

News Sentiment
STAAR Surgical has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for STAAR Surgical this week, compared to 4 articles on an average week.
Search Interest
7 people have searched for STAA on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added STAAR Surgical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, STAAR Surgical insiders have bought 8,457.06% more of their company's stock than they have sold. Specifically, they have bought $4,364,185.00 in company stock and sold $51,001.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of STAAR Surgical is held by insiders.
Percentage Held by Institutions
97.55% of the stock of STAAR Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for STAAR Surgical are expected to grow by 104.48% in the coming year, from $0.67 to $1.37 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of STAAR Surgical is 81.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.78.
Price to Earnings Ratio vs. Sector
The P/E ratio of STAAR Surgical is 81.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.62.
Price to Book Value per Share Ratio
STAAR Surgical has a P/B Ratio of 9.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Stock News Headlines

March 24, 2023 | marketwatch.com

Ophthalmic Equipment Market Top Players By 2031

March 24, 2023 | americanbankingnews.com

STAAR Surgical (NASDAQ:STAA) Stock Price Down 3.2%

March 27, 2023 | Tradewins (Ad)

Modern Day Options Trading For Beginners!

These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market.

March 24, 2023 | marketwatch.com

Cataract Surgery Devices Market Outlook By 2031

March 23, 2023 | marketwatch.com

Intraocular Lens (IOL) Material Market Size, Trends and Forecast 2028

March 19, 2023 | americanbankingnews.com

STAAR Surgical (NASDAQ:STAA) Research Coverage Started at StockNews.com

March 14, 2023 | msn.com

STAAR Surgical gains after reaffirming sales forecast

March 14, 2023 | marketwatch.com

Monofocal IOLs Market Application, Product, Sales and Forecast 2023-2028

March 27, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 13, 2023 | finance.yahoo.com

Implied Volatility Surging for STAAR Surgical (STAA) Stock Options

March 10, 2023 | marketwatch.com

Ophthalmology Cataract Surgery Devices Market Application, Product, Sales and Forecast 2023-2028

March 9, 2023 | finance.yahoo.com

Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

March 8, 2023 | marketwatch.com

Ophthalmic Surgical Instruments Market Application, Product, Sales and Forecast 2023-2028

March 1, 2023 | marketwatch.com

Ophthalmology Surgical Devices Market Industry Analysis, Estimates Size and Projections by 2029

February 27, 2023 | marketwatch.com

Ophthalmic Surgical Devices Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028

February 24, 2023 | seekingalpha.com

STAAR Surgical Shines In Today's Uncertainties Due To Growing U.S. Revenue

February 24, 2023 | marketwatch.com

Ophthalmology Surgical Devices Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028

February 23, 2023 | finance.yahoo.com

STAAR Surgical Full Year 2022 Earnings: EPS: US$0.81 (vs US$0.52 in FY 2021)

February 23, 2023 | markets.businessinsider.com

Mizuho Securities Keeps Their Buy Rating on Staar Surgical (STAA)

February 22, 2023 | benzinga.com

STAAR Surgical shares are trading lower after the company reported mixed Q4 financial results.

February 22, 2023 | markets.businessinsider.com

Stephens Keeps Their Buy Rating on Staar Surgical (STAA)

February 22, 2023 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on LENSAR (LNSR)

February 21, 2023 | msn.com

STAAR Surgical falls as 2023 outlook disappoints

February 21, 2023 | finance.yahoo.com

Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates

February 21, 2023 | finance.yahoo.com

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results

February 20, 2023 | marketwatch.com

Ophthalmic Devices Market 2023 : Global Industry Share, Key Dynamics and Forecast to 2028

February 18, 2023 | seekingalpha.com

STAA STAAR Surgical Company

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Company Calendar

Last Earnings: 11/03/2021
Today: 3/27/2023
Next Earnings (Estimated): 5/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Ophthalmic goods
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:STAA
CUSIP: 85231230
CIK: 718937
Web: www.staar.com
Phone: (626) 303-7902
Fax: 626-303-2962
Employees: 692
Year Founded: 1982

Price Target and Rating

Average Stock Price Forecast: $82.20
High Stock Price Forecast: $125.00
Low Stock Price Forecast: $60.00
Forecasted Upside/Downside: +30.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.78
Trailing P/E Ratio: 80.74
Forward P/E Ratio: 94.00
P/E Growth: N/A
Net Income: $38.76 million
Net Margins: 13.63%
Pretax Margin: 16.02%
Return on Equity: 12.91%
Return on Assets: 10.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.03
Quick Ratio: 5.56

Sales & Book Value

Annual Sales: $284.39 million
Price / Sales: 10.68
Cash Flow: $0.88 per share
Price / Cash Flow: 71.34
Book Value: $6.89 per share
Price / Book: 9.14

Miscellaneous

Outstanding Shares: 48,240,000
Free Float: 46,982,000
Market Cap: $3.04 billion
Optionable: Optionable
Beta: 1.23

Social Links

Key Executives

Thomas G. Frinzi
Chairman, President & Chief Executive Officer

Patrick F. Williams
Chief Financial Officer & Vice President

Keith Holliday
Chief Technology Officer

Scott D. Barnes
Chief Medical Officer

Samuel J. Gesten
Secretary & Chief Legal Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STAA Stock - Frequently Asked Questions

Should I buy or sell STAAR Surgical stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STAA shares.
View STAA analyst ratings or view top-rated stocks.
What is STAAR Surgical's stock price forecast for 2023?: 10 brokerages have issued 12 month target prices for STAAR Surgical's stock. Their STAA share price forecasts range from $60.00 to $125.00. On average, they predict the company's share price to reach $82.20 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts price targets for STAA or view top-rated stocks among Wall Street analysts.
How have STAA shares performed in 2023?: STAAR Surgical's stock was trading at $48.54 at the beginning of the year. Since then, STAA stock has increased by 29.7% and is now trading at $62.98.
View the best growth stocks for 2023 here.
When is STAAR Surgical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our STAA earnings forecast.
How were STAAR Surgical's earnings last quarter?: STAAR Surgical (NASDAQ:STAA) issued its earnings results on Wednesday, November, 3rd. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The medical instruments supplier had revenue of $58.35 million for the quarter, compared to the consensus estimate of $57.70 million. STAAR Surgical had a net margin of 13.63% and a trailing twelve-month return on equity of 12.91%. During the same quarter in the previous year, the company posted $0.14 earnings per share.
What ETFs hold STAAR Surgical's stock?: ETFs with the largest weight of STAAR Surgical (NASDAQ:STAA) stock in their portfolio include Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Pacer US Export Leaders ETF (PEXL), Janus Henderson US Sustainable Equity ETF (SSPX), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and AI Powered Equity ETF (AIEQ).
What guidance has STAAR Surgical issued on next quarter's earnings?: STAAR Surgical updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.00 million-$340.00 million, compared to the consensus revenue estimate of $343.34 million.
What is Caren Mason's approval rating as STAAR Surgical's CEO?: 6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

What other stocks do shareholders of STAAR Surgical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).
What is STAAR Surgical's stock symbol?: STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."
Who are STAAR Surgical's major shareholders?: STAAR Surgical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.86%), Geneva Capital Management LLC (1.95%), E Fund Management Co. Ltd. (1.87%), Geode Capital Management LLC (1.87%), Principal Financial Group Inc. (1.42%) and Morgan Stanley (1.10%). Insiders that own company stock include Broadwood Partners, LP, Caren L Mason, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, Patrick F Williams and Samuel J Gesten.
View institutional ownership trends.
How do I buy shares of STAAR Surgical?: Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is STAAR Surgical's stock price today?: One share of STAA stock can currently be purchased for approximately $62.98.
How much money does STAAR Surgical make?: STAAR Surgical (NASDAQ:STAA) has a market capitalization of $3.04 billion and generates $284.39 million in revenue each year. The medical instruments supplier earns $38.76 million in net income (profit) each year or $0.78 on an earnings per share basis.
How many employees does STAAR Surgical have?: The company employs 692 workers across the globe.
Does STAAR Surgical have any subsidiaries?: The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.
Read More
How can I contact STAAR Surgical?: STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.

This page (NASDAQ:STAA) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

STAAR Surgical - STAA Stock Forecast, Price & News

STAAR Surgical MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About STAAR Surgical (NASDAQ:STAA) Stock

STAA Stock News Headlines

STAA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

STAA Stock - Frequently Asked Questions

Overall MarketRank^™